Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor
XTalks
FEBRUARY 27, 2024
Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.” Amtagvi Considerations Amtagvi’s approval was decades in the making, with TIL therapy dating back to research conducted at the National Institutes of Health (NIH) in the 1980s.
52 
Let's personalize your content